Small constrained SP1–7 analogs bind to a unique site and promote anti-allodynic effects following systemic injection in mice

Highlights • The neuropeptide SP1–7 attenuates signs of allodynia in the SNI mouse model. • One low molecular weight SP1–7 analog exhibits an anti-allodynic activity. • An extensive target screen did not reveal the binding site of SP1–7.

Saved in:
Bibliographic Details
Published inNeuroscience Vol. 298; pp. 112 - 119
Main Authors Jonsson, A, Fransson, R, Haramaki, Y, Skogh, A, Brolin, E, Watanabe, H, Nordvall, G, Hallberg, M, Sandström, A, Nyberg, F
Format Journal Article
LanguageEnglish
Published United States Elsevier Ltd 09.07.2015
Subjects
Analgesics - therapeutic use
Animals
anti-allodynia
Area Under Curve
Binding Sites - drug effects
Disease Models, Animal
Hyperalgesia - drug therapy
Male
Mice
Neuralgia - drug therapy
Neuralgia - metabolism
Neurology
Pain Measurement
Pain Threshold - drug effects
Peptide Fragments - chemistry
Peptide Fragments - therapeutic use
peptidomimetics
Protein Binding - drug effects
receptor screening
SP1–7
spared nerve injury
Statistics, Nonparametric
substance P (SP)
Substance P - chemistry
Substance P - therapeutic use
Time Factors
spinal cord injury
intraperitoneal
anti-allodynia
i.p
NK 1
EM-2
SP 1–7
SNI
receptor screening
substance P (SP)
analysis of variance
endomorphin-2
ANOVA
SCI
peptidomimetics
substance P
neurokinin-1
spared nerve injury
SP
SP1–7
NK1
SP(1–7)
Online AccessGet full text

Cover

More Information
Summary:Highlights • The neuropeptide SP1–7 attenuates signs of allodynia in the SNI mouse model. • One low molecular weight SP1–7 analog exhibits an anti-allodynic activity. • An extensive target screen did not reveal the binding site of SP1–7.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0306-4522
1873-7544
DOI:10.1016/j.neuroscience.2015.04.002